natgillin/translations-raw huggingface dataset:
If you get any symptoms of infection or if you notice any of the symptoms above: 
Če se vam pojavi kakšen simptom okužbe, ali če opazite katerega od zgornjih simptomov:
Further management should be as recommended by the national poisons centre, where available. 
Nadaljnje vodenje mora potekati po priporočilih nacionalnega centra za zastrupitve, če so na voljo.
Demographic and Baseline Characteristics 
Demografske in izhodiščne značilnosti
Talk to your doctor if this applies to you. 
Posvetujte se z zdravnikom, če to velja za vas.
• low blood pressure, including dizziness when you stand up or sit up quickly, or if you are taking any medicines to lower blood pressure. 
• nizek krvni tlak vključno z omotico, kadar hitro vstanete ali se vsedete ali v primeru, da jemljete kakšna zdravila za zniževanje krvnega tlaka.
CELSENTRI has only been taken by limited numbers of people 65 years or older. 
Zdravilo CELSENTRI je jemalo le malo število ljudi, starih 65 let ali več.
If you or your child stop taking CELSENTRI 
Če ste vi ali vaš otrok prenehali jemati zdravilo CELSENTRI
Contains soya lecithin: see leaflet for further information. 
SEZNAM POMOŽNIH SNOVI Vsebuje sojin lecitin: za dodatne informacije glejte navodilo za uporabo.
If you (or your child) miss a dose of CELSENTRI, take or give the missed dose as soon as possible and then continue with the next dose at its regular time. 
Če vi (ali vaš otrok) pozabite vzeti odmerek zdravila CELSENTRI, pozabljeni odmerek vzemite ali dajte čim prej in nato nadaljujte z naslednjim odmerkom ob običajnem času.
Age (years) (Range, years) 
Starost (leta) (Razpon, leta) Moški
Stop taking CELSENTRI. 
Prenehajte jemati zdravilo CELSENTRI.
Approximately 20% of the radiolabel was recovered in the urine and 76% was recovered in the faeces over 168 hours. 
Približno 20 % radioaktivnosti se je pojavilo v urinu in 76 % v blatu v 168 urah.
These medicines are all called anti-HIV medicines or antiretrovirals. 
Imenujemo jih zdravila proti HIV ali protiretrovirusna zdravila.
Contact your doctor or the nearest hospital immediately. 
se nemudoma posvetujte z zdravnikom ali kontaktirajte najbližjo bolnišnico.
The corresponding paediatric dose can then be obtained from Table 1 below. 
Ustrezen pediatrični odmerek lahko potem razberete iz preglednice 1, spodaj.
Hence, the relevance of these mutations to maraviroc susceptibility in other viruses is not known. 
Zato pomen teh mutacij za občutljivost za maravirok pri drugih virusih ni znana.
Don't take other medicines for the infection without your doctor's advice. 
Za okužbo ne vzemite nobenih drugih zdravil, ne da bi se posvetovali z zdravnikom.
Read the information ‘Other possible side effects of combination therapy for HIV' in Section 4 of this leaflet. 
Preberite informacije "Drugi možni neželeni učinki kombiniranega zdravljenja okužbe z virusom HIV" v poglavju 4 tega navodila.
OBT: Optimised Background Therapy * Percentages based on total patients evaluated for each laboratory parameter 
OOT: optimizirana osnovna terapija * Odstotki temeljijo na celotnem številu bolnikov, ovrednotenih za vsak laboratorijski parameter.
Keep taking CELSENTRI until your doctor tells you to stop. 
Zdravilo CELSENTRI jemljite, dokler vam zdravnik ne naroči, da ga prenehajte jemati.
Any inflammatory symptoms should be evaluated and treatment initiated when necessary. 
Vsak simptom vnetja, ki se pojavi, je treba oceniti in uvesti zdravljenje, kadar je potrebno.
Therefore, CELSENTRI should be used with caution in this population. 
Zato je treba zdravilo CELSENTRI pri tej populaciji uporabljati previdno.
Don't drive, cycle, or operate tools or machines unless you are sure you're not affected. 
Ne upravljajte vozil, ne kolesarite, ne uporabljajte orodij in ne upravljajte strojev, dokler niste prepričani, da nimate te težave.
Stevens-Johnson syndrome / Toxic epidermal necrolysis rare / not known 
Stevens-Johnsonov sindrom/toksična epidermalna nekroliza redki/neznana
Maraviroc was evaluated for carcinogenic potential by a 6 month transgenic mouse study and a 24 month study in rats. 
Kancerogeni potencial maraviroka so ocenili s 6-mesečno študijo pri transgenskih miših in 24-mesečno študijo pri podganah.
Special patient populations: 
Posebne populacije bolnikov:
It is not known whether the ingredients in CELSENTRI can also pass into breast milk. 
Ni znano, ali sestavine zdravila CELSENTRI lahko prehajajo v materino mleko.
The position of these mutations was not consistent between different isolates. 
Položaj mutacij se med različnimi izolati ni skladal.
CD4 cells are a type of white blood cell that are important in helping your body to fight infection. 
CD4 celice so bele krvne celice, ki pomagajo telesu v boju proti okužbi.
Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance. 
Kot pomoč za odstranitev neabsorbiranega zdravila je mogoče uporabiti aktivno oglje.
This helps your body to increase the CD4 cell count in your blood. 
To pomaga telesu, da proizvede večje število CD4 celic v krvi.
In the remaining 36 patients, there was no evidence of virus with reduced sensitivity as identified by exploratory virology analyses on a representative group. 
Pri preostalih 36 bolnikih ni bilo znakov za virus z zmanjšano občutljivostjo, kot so ugotovile eksploracijske virološke analize v reprezentativni skupini.
The date should be written as soon as the bottle has been opened for first use. 
Datum je treba vpisati takoj, ko je plastenka prvič odprta za uporabo.
You should not take them while you're taking CELSENTRI. 
Zato jih ne smete jemati, medtem ko jemljete zdravilo CELSENTRI.
CELSENTRI, as part of combination therapy, reduces the amount of virus in your body, and keeps it at a low level. 
Zdravilo CELSENTRI kot del kombinirane terapije zmanjša količino virusa HIV v telesu in jo ohrani na nizki ravni.
The antiviral activity of maraviroc against HIV-2 has not been evaluated. 
Protivirusno delovanje maraviroka proti HIV-2 ni ocenjeno.
Taking your medicines at the right time every day is important, as it makes sure the HIV infection does not increase in your body. 
Pomembno je, da zdravilo jemljete vsak dan ob pravem času, saj to zagotavlja, da se okužba s HIV v vašem telesu ne širi.
Rifabutin is considered to be a weaker inducer than rifampicin. 
Rifabutin velja za šibkejši induktor kot rifampicin.
This will allow your doctor to prescribe the right dose of CELSENTRI. 
Tako vam bo zdravnik lahko predpisal pravilni odmerek zdravila CELSENTRI.
Insert the applicator (C) firmly into the adapter. 
Aplikator (C) trdno vstavite v nastavek.
Available toxicological data in animals has shown extensive excretion of maraviroc in milk. 
Razpoložljivi toksikološki podatki pri živalih kažejo na obsežno izločanje maraviroka v mleko.
If you forget to take or give CELSENTRI 
Če ste pozabili vzeti ali dati zdravilo CELSENTRI
Primary pharmacological activity (CCR5 receptor affinity) was present in the monkey (100% receptor occupancy) and limited in the mouse, rat, rabbit and dog. 
Primarna farmakološka aktivnost (afiniteta za CCR5 receptor) je bila prisotna pri opicah (100 % zasedenost receptorja) in omejena pri miših, podganah, kuncih in psih.
Pfizer Service Company, Hoge Wei 10, B 1930 Zaventem, Belgium 
Izdelovalec Pfizer Service Company, Hoge Wei 10, B 1930 Zaventem, Belgija
Data to support these doses are lacking and CELSENTRI is not recommended in children taking concomitant interacting medicinal products that in adults would require a 600 mg twice daily dose. 
Podatkov v podporo tem odmerkom ni in zdravilo CELSENTRI ni priporočeno za otroke, ki sočasno jemljejo zdravila z medsebojnim delovanjem, zaradi katerih bi bil pri odraslih potreben odmerek 600 mg dvakrat na dan.
Breast-feeding Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk. 
Ženske, ki so HIV pozitivne, ne smejo dojiti otrok, kajti okužba z virusom HIV se lahko prenese na otroka z materinim mlekom.
To date, no signature mutation(s) have been identified. 
Doslej niso identificirali nobenih podpisnih mutacij.
Etravirine is only approved for use with boosted protease inhibitors. 
Etravirin je odobren samo za uporabo z okrepljenimi zaviralci proteaz.
In case of concomitant antiviral therapy for hepatitis B and/or C, please refer to the relevant product information for these medicinal products. 
V primeru sočasnega protivirusnega zdravljenja hepatitisa B in/ali C glejte tudi ustrezne informacije o teh zdravilih.
Some people taking CELSENTRI have developed severe and life-threatening skin reactions and allergic reactions. 
Nekaterim ljudem, ki so jemali zdravilo CELSENTRI, so se pojavile hude in življenjsko ogrožajoče kožne reakcije in alergijske reakcije.
No relevant difference between Caucasian, Asian and Black subjects has been observed. 
Med belci, azijci in črnci niso opazili pomembne razlike.
The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. 
Simptomi avtoimunskih bolezni se lahko pojavijo veliko mesecev po začetku jemanja zdravila za zdravljenje okužbe z virusom HIV.
The safety and efficacy of maraviroc have not been specifically studied in patients with significant underlying liver disorders. 
Varnost in učinkovitost maraviroka nista specifično raziskani pri bolnikih s pomembno osnovno boleznijo jeter.
Therefore, dosing frequencies of longer than 24 hours in subjects with renal impairment may result in inadequate exposures between 24-48 hours. 
Če je presledek med odmerki pri bolnikih z okvaro ledvic daljši od 24 ur, se zato lahko v času od 24 do 48 ur pojavi nezadostna izpostavljenost.
The absorption of maraviroc is variable with multiple peaks. 
Absorpcija maraviroka je variabilna z mnogimi vrhovi.
Some medicines may change the amount of CELSENTRI in the body when they are taken at the same time as CELSENTRI. 
Nekatera zdravila lahko spremenijo količino zdravila CELSENTRI v telesu, če jih vzamete sočasno z zdravilom CELSENTRI.
If you are allergic to peanut or soya do not use this medicinal product. 
Če ste alergični na arašide ali sojo, ne uporabljajte tega zdravila.
In mice and human beings that lack CCR5 receptors through genetic deletion, no significant adverse consequences have been reported. 
Pri miših ter ljudeh, ki zaradi genske delecije nimajo CCR5 receptorjev, niso poročali o pomembnih neželenih učinkih.
Please also refer to the respective Summary of Product Characteristics of the other antiretroviral medicinal products used in the combination. 
Prosimo, glejte tudi ustrezne povzetke glavnih značilnosti zdravila za druga protiretrovirusna zdravila, uporabljena v kombinaciji.
This polar metabolite has no significant pharmacological activity. 
Ta polarni presnovek nima pomembnega farmakološkega delovanja.
This subgroup had a high degree of bad prognostic markers, i.e. extensive resistance and high baseline viral loads. 
Ta podskupina je imela veliko slabih prognostičnih označevalcev, tj. izdatno odpornost in veliko izhodiščno virusno breme.
Your doctor must take blood samples to test whether CELSENTRI is an appropriate treatment for you (or your child, if they are the patient). 
Zdravnik vam mora vzeti kri za preiskave, s katerimi bo ugotovil, ali je zdravilo CELSENTRI za vas primerno zdravilo (ali za vašega otroka, če je bolnik on).
Some people taking medicines for HIV infection develop other conditions, which can be serious. 
Nekaterim bolnikom, ki jemljejo zdravila za okužbo s HIV, se pojavijo druga stanja, ki so lahko resna.
No relevant differences in pharmacokinetics have been observed. 
Niso opazili pomembnih razlik v farmakokinetiki.
Medicinal product by therapeutic areas (dose of CELSENTRI used in study) 
Zdravila po terapevtskih področjih (v študiji uporabljeni odmerek zdravila CELSENTRI)
Other metabolites are products of mono-oxidation and are only minor components of plasma radioactivity. 
Drugi presnovki nastanejo z monooksidacijo in so le manj pomembne komponente radioaktivnosti v plazmi.
 Tell your doctor. 
Obvestite zdravnika.
Prior to deciding the dose of CELSENTRI by weight, please refer to Table 2 in section 4.5 to carefully determine the corresponding adult dose. 
Pred določitvijo odmerka zdravila CELSENTRI glede na telesno maso skrbno preglejte preglednico 2 v poglavju 4.5, da boste natančno določili ustrezen odmerek za odrasle.
• liver problems, including chronic hepatitis B or C. Only a limited number of people with liver problems have taken CELSENTRI. 
• težave z jetri, vključno s kroničnim hepatitisom B ali C. Zdravilo CELSENTRI je namreč jemalo le malo bolnikov, ki so imeli težave z jetri.
 old, hidden infections flaring up again as the body fights them  the immune system attacking healthy body tissue (autoimmune disorders). 
 stare, prikrite okužbe, ki se znova razplamtijo, ko se telo z njimi bori, ali  napad imunskega sistema na zdrava tkiva lastnega telesa (avtoimunske bolezni).
Number of active ARVs in OBT1: 
Število aktivnih PRZ v OOT1:
You (or your child) can still pass on HIV when taking this medicine, although the risk is lowered by effective treatment. 
Med jemanjem tega zdravila lahko vi (ali vaš otrok) še vedno prenesete okužbo s HIV na druge, čeprav učinkovito zdravljenje to tveganje zmanjša.
Hold the bottle firmly. 
Trdno primite plastenko.
Interaction not studied. 
Interakcij niso raziskali.
What CELSENTRI is and what it is used for 
Kaj je zdravilo CELSENTRI in za kaj ga uporabljamo
Symptoms of infection and inflammation may develop, caused by either: 
Pojavijo se lahko simptomi okužbe in vnetja, ki jih povzročijo ali:
Keep it safely 2. 
Varno ga shranite.
The adverse reactions and laboratory abnormalities presented below are not exposure adjusted. 
Spodaj navedeni neželeni učinki in laboratorijske nepravilnosti niso prilagojeni glede na izpostavljenost.
The latter group had markers correlating to low compliance (low and variable drug levels and often a calculated high residual sensitivity score of the OBT). 
Ta skupina je imela značilnosti, ki ustrezajo nizki komplianci (nizke in spremenljive ravni zdravila ter pogosto izračunana visoka rezidualna občutljivost OOT).
Overall, the safety profile in paediatric patients was similar to that observed in adult clinical studies. 
V celoti so bile varnostne značilnosti pri pediatričnih bolnikih podobne kot v kliničnih študijah pri odraslih.
The most significant circulating metabolite in humans is a secondary amine (approximately 22% radioactivity) formed by N-dealkylation. 
Najpomembnejši presnovek v obtoku pri človeku je sekundarni amin (približno 22 % radioaktivnosti), ki nastane z N-dealkilacijo.
22.5% Odds ratio: 4.76 
22,5 % Razmerje obetov: 4,76
Studies with the tablets demonstrated a reduced foodeffect at higher doses. 
Študije s tabletami so pokazale manjši vpliv hrane pri večjih odmerkih.
Angina pectoris rare 
Srčne bolezni angina pektoris redki
People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). 
Osebe z napredovalo okužbo s HIV (AIDS) imajo oslabel imunski sistem in so bolj nagnjene k pojavu resnih okužb (oportunističnih okužb).
It may not be excluded that maraviroc can increase the exposure to the P-glycoprotein substrate dabigatran etexilate. 
Ni mogoče izključiti, da maravirok poveča izpostavljenost substratu P-glikoproteina dabigatran-eteksilatu.
At higher exposure of maraviroc a potential inhibition of CYP2D6 cannot be excluded. 
Pri višji izpostavljenosti maraviroku ni mogoče izključiti potencialnega zaviranja CYP2D6.
Children from 2 years of age and weighing at least 10kg The recommended dose of CELSENTRI should be based on body weight (kg) and should not exceed the recommended adult dose. 
Otroci, starejši od 2 let in s telesno maso vsaj 10 kg Priporočeni odmerek zdravila CELSENTRI mora temeljiti na telesni masi (kg) in ne sme preseči priporočenega odmerka za odrasle.
The recommended dose of CELSENTRI differs depending on interactions with concomitant antiretroviral therapy and other medicinal products. 
Priporočeni odmerek zdravila CELSENTRI se razlikuje glede na medsebojna delovanja s sočasnim protiretrovirusnim zdravljenjem in drugimi zdravili.
Maraviroc is bound (approximately 76%) to human plasma proteins, and shows moderate affinity for albumin and alpha-1 acid glycoprotein. 
Maravirok je (približno 76-odstotno) vezan na beljakovine v človeški plazmi in ima zmerno afiniteto za albumin in alfa-1-kisli glikoprotein.
• feeling weak or lack of energy, anaemia (seen in blood test result) 
• občutek šibkosti ali pomankanje energije, anemija (pokaže se na preiskavah krvi),
These adverse reactions were common (≥ 1/100 to < 1/10). 
Ti neželeni učinki so bili pogosti (≥ 1/100 do < 1/10).
There is limited experience in patients >65 years of age (see section 5.2), therefore CELSENTRI should be used with caution in this population. 
Izkušnje pri bolnikih, starejših od 65 let, so omejene (glejte poglavje 5.2), zato je treba pri tej populaciji zdravilo CELSENTRI uporabljati previdno.
Some people taking CELSENTRI have developed serious allergic reactions or skin reactions (see also ‘Serious side effects' in section 4). 
Nekaterim osebam, ki so jemale zdravilo CELSENTRI, so se pojavile resne alergijske reakcije ali kožne reakcije (glejte tudi "Resni neželeni učinki" v poglavju 4).
Oral solution Pfizer Service Company Hoge Wei 10 
Peroralna raztopina Pfizer Service Company Hoge Wei 10
Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX09 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, druga zdravila za sistemsko zdravljenje virusnih infekcij, oznaka ATC: J05AX09
16.7% Odds ratio: 4.49 
16,7 % Razmerje obetov: 4,49
• fever (high temperature). 
• povišana telesna temperatura (vročina).
2 What you need to know before you take CELSENTRI Do not take CELSENTRI: 
Kaj morate vedeti, preden boste vzeli zdravilo CELSENTRI Ne jemljite zdravila CELSENTRI:
All subjects (n = 103) received maraviroc twice daily and OBT. 
Vsi preiskovanci (n = 103) so prejemali maravirok dvakrat na dan in OOT.
• headache, problems sleeping,depression 
• glavobol, težave s spanjem, depresija,
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) , or not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥1/10.000 do <1/1.000) ali neznano (ni mogoče oceniti iz razpoložljivih podatkov).
DRUG ABUSE Methadone 
ZLORABA ZDRAVIL Metadon
The gp120 amino acid substitutions identified so far are context dependent and inherently unpredictable with regards to maraviroc susceptibility. 
Doslej identificirane substitucije aminokislin gp120 so odvisne od konteksta in so same po sebi nepredvidljive, kar zadeva občutljivost za maravirok.
Clinical status and relevant blood chemistry should be monitored and appropriate symptomatic therapy initiated. 
Kontrolirati je treba klinično stanje in pomembne laboratorijske izvide krvi ter uvesti ustrezno simptomatsko zdravljenje.
• drowsiness and confusion 
• zaspanost in zmedenost,
It is recommended that mothers infected by HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV. 
Priporočljivo je, da ženske okužene z virusom HIV v nobenem primeru ne dojijo, saj s tem preprečijo prenos virusa HIV.
Your doctor will advise you whether it is better to take CELSENTRI oral solution, if you (or your child) are unable to swallow tablets. 
Zdravnik vam bo povedal, ali je bolje, da uporabljate peroralno raztopino zdravila CELSENTRI, če vi (ali vaš otrok) ne morete pogoltniti tablet.
Genotypic resistance 
Genotipska odpornost
Other possible side effects of combination therapy for HIV 
Drugi možni neželeni učinki kombiniranega zdravljenja HIV
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. 
Bolnikom je treba povedati, da naj se posvetujejo s svojim zdravnikom, če se jim pojavijo bolečine v sklepih, togost sklepov ali težave pri gibanju.
Do not take or give a double dose to make up for a forgotten dose. 
Ne vzemite ali dajte dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
The serum adjusted EC90 value in 43 primary HIV-1 clinical isolates was 0.57 (0.06 - 10.7) ng/mL without significant changes between different subtypes tested. 
Za serum prilagojena vrednost EC90 v 43 primarno HIV-1 kliničnih izolatih je bila 0,57 (0,06-10,7) ng/ml, brez bistvenih sprememb med različnimi testiranimi podvrstami.
CELSENTRI contains soya lecithin. 
Zdravilo CELSENTRI vsebuje sojin lecitin.
• ritonavir-boosted protease inhibitors (with the exception of tipranavir/ritonavir), 
• z ritonavirjem okrepljeni zaviralci proteaz (razen kombinacije tipranavir/ritonavir),
For details please refer to the pharmacology section of the CELSENTRI European Public Assessment Report (EPAR) on the European Medicines Agency (EMA) website. 
Za podrobnosti glejte farmakološko poglavje Evropskega javnega poročila o oceni zdravila (EPAR) CELSENTRI, ki je dostopno na spletni strani Evropske agencije za zdravila (EMA).
If a patient is hypersensitive to peanut or soya, CELSENTRI should not be used. 
Če je bolnik preobčutljiv za arašide ali sojo, zdravila CELSENTRI ne sme uporabljati.
If you take or give more CELSENTRI than you should 
Če ste vzeli ali dali večji odmerek zdravila CELSENTRI, kot bi smeli
Table 2: Interactions and adulta dose recommendations with other medicinal products 
Preglednica 2: Medsebojno delovanje in priporočeni odmerki za odraslea skupaj z drugimi zdravili
In rabbit, 7 foetuses had external anomalies at maternally toxic doses and 1 foetus at the mid dose of 75 mg/kg. 
Pri kuncih je imelo 7 zarodkov zunanje anomalije pri odmerkih, ki so bili toksični za samico mater, in 1 zarodek pri srednjem odmerku 75 mg/kg.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
• Načrt za obvladovanje tveganj (RMP) Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP.
Cases of syncope caused by postural hypotension have been reported. 
Poročali so o primerih sinkope povzročene zaradi posturalne hipotenzije.
If a child is unable to reliably swallow CELSENTRI tablets, the oral solution (20 mg per mL) should be prescribed (refer to Summary of Product Characteristics for CELSENTRI oral solution). 
Če otrok ne more zanesljivo pogoltniti tablet zdravila CELSENTRI, mu je treba predpisati peroralno raztopino (20 mg/ml) (glejte povzetek glavnih značilnosti zdravila CELSENTRI peroralna raztopina).
Residual activity in vivo for viruses with MPI-values <95% has not been determined. 
Preostale in vivo aktivnosti virusov z MPI vrednostmi <95% niso določili.
CELSENTRI works by blocking a receptor called CCR5 which HIV uses to enter and infect your blood cells. 
Zdravilo CELSENTRI deluje tako, da blokira receptor CCR5, ki ga virus HIV uporablja za vstopanje v krvne celice in njihovo okužbo.
A randomised, double-blinded study (MERIT), explored maraviroc versus efavirenz, both in combination with zidovudine/lamivudine (n=721, 1:1). 
V dvojno slepi randomizirani študiji (MERIT), so raziskovali maravirok v primerjavi z efavirenzom, oba v kominaciji z zidovudinom/lamivudinom (n=721, 1:1).
Doses were given with food on intensive pharmacokinetic evaluation days and optimised to achieve an average concentration over the dosing interval (Cavg) of greater than 100 ng/mL; otherwise, maraviroc was given with or without food. 
Bolniki so odmerke na dan intenzivnega vrednotenja farmakokinetike dobili s hrano, optimizirane tako, da je bila med odmernim intervalom dosežena povprečna koncentracija (Cpovp) več kot 100 ng/ml; sicer pa so maravirok jemali s hrano ali brez nje.